Brookline Capital Management Comments on VRCA Q1 Earnings

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Equities research analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for Verrica Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 11th. Brookline Capital Management analyst K. Dolliver expects that the company will earn ($0.10) per share for the quarter. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.46) per share. Brookline Capital Management also issued estimates for Verrica Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.34) EPS.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.30 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%.

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.50.

Verrica Pharmaceuticals Stock Down 1.4 %

Shares of VRCA stock opened at $0.59 on Thursday. The stock has a 50 day moving average of $0.68 and a 200-day moving average of $1.11. The firm has a market cap of $26.95 million, a PE ratio of -0.32 and a beta of 1.44. Verrica Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $11.41.

Institutional Trading of Verrica Pharmaceuticals

Several institutional investors have recently modified their holdings of VRCA. Geode Capital Management LLC raised its stake in shares of Verrica Pharmaceuticals by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock valued at $334,000 after buying an additional 21,789 shares in the last quarter. Barclays PLC boosted its position in shares of Verrica Pharmaceuticals by 404.6% during the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after acquiring an additional 25,130 shares in the last quarter. Jane Street Group LLC increased its stake in Verrica Pharmaceuticals by 106.5% in the third quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after acquiring an additional 36,028 shares during the period. Invesco Ltd. acquired a new position in Verrica Pharmaceuticals in the fourth quarter worth about $32,000. Finally, Sanctuary Advisors LLC acquired a new position in Verrica Pharmaceuticals in the third quarter worth about $87,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.